Review Article

Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization

Table 1

Selected clinical studies of monoclonal antibodies used for the treatment of ovarian cancer.

AntibodyMechanism of actionRepresentative Phase II studiesPhase III studies
PopulationTreatmentResultsPopulationTreatmentResults

Bevacizumab (Genentech/Roche)Binds to VEGF Antiangiogenic ImmunosuppressiveRefractory ( ) [145]Monotherapy ( ) With chemotherapy ( )RR 16%
PFS 5.5 m
OS 6.9 m
First-line ICON 7 [146]Carboplatin/Paclitaxel versus
Carboplatin/Paclitaxel/Bevacizum ab
Median PFS 17.3 m versus
19 m, 10.3 m versus
11.2 m versus
14.1,
Refractory ( ) [147]MonotherapyRR 16%
PFS 4.4 m
OS 10.7
GOG 218 [148]Carboplatin/Paclitaxel versus
Carboplatin/Paclitaxel/Bevacizum ab
versus
Carboplatin/Paclitaxel/Bevacizum ab
+ Bevacizumab maintenance

Oregovomab (AltaRex Corp)Binds to CA125 Development of a humoral and cellular antitumor response2nd line treatment ( ) [149]With chemotherapyDevelopment of T cell response was associated with improved survivalMaintenance after first-line ( ) [150]Oregovomab versus
placebo
Median PFS 13.3 m versus 10.3 m,

Maintenance after first-line Residual<2 cm, CA125 < 65 after 3rd cycle, CA1 at entry ( )Oregovomab versus
placebo
Awaited

Trastuzumab (Genentech)Binds to HER2 extracellular domainRecurrent ( ) [141]MonotherapyRR 7.3% PFS 2 m

Pertuzumab (Genentech)Inhibitor of HER dimerization87% platinum-resistant ( ) [151]monotherapyRR 4.3% PFS 6.6 w

Cetuximab (Bristol-Myers Squibb)EGFR inhibitorFirst-line ( ) [152]Combination with paclitaxel/carboplatinPFS 14.4 m

Matuzumab (Merck/Serono/Takeda)EGFR inhibitorPlatinum-resistant ( ) [153]MonotherapyRR 16.2 m TTP 54d OS 13.3 m